Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Metastatic colorectal cancer (mCRC) treatment relies on limited molecular markers.
• Molecular classification of CRC aids in understanding tumor biology and tailoring therapy.
• Microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) is a key biomarker for immune checkpoint inhibitor (ICI) therapy in mCRC.

Purpose of the Study:

• To review molecular characteristics influencing response to ICI in mCRC.
• To identify microRNAs that modulate PD-L1 expression and immune evasion mechanisms.
• To enhance patient outcomes in mCRC through targeted therapies.

Main Methods:

• Comprehensive literature review using the PubMed database.
• Analysis of molecular traits associated with tumor response to ICI therapies.
• Investigation of microRNA roles in regulating PD-L1 and immune evasion.

Main Results:

• ICI therapies show improved outcomes in mCRC patients with MSI-H/dMMR status.
• Tumor PD-L1 expression is linked to immune evasion in CRC.
• Specific microRNAs have the potential to target PD-L1 and overcome ICI resistance.

Conclusions:

• Understanding molecular drivers of ICI response is crucial for mCRC treatment optimization.
• Targeting microRNAs offers a novel strategy to enhance ICI efficacy by modulating PD-L1.
• Further research into microRNA-PD-L1 interactions can lead to improved therapeutic approaches for mCRC.